In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $24.73 in the prior trading day, Moderna Inc (NASDAQ: MRNA) closed at $25.1, up 1.50%. In other words, the price has increased by $1.50 from its previous closing price. On the day, 18.63 million shares were traded. MRNA stock price reached its highest trading level at $25.64 during the session, while it also had its lowest trading level at $24.28.
Ratios:
Our goal is to gain a better understanding of MRNA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.77 and its Current Ratio is at 3.93. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Neutral rating and assigned the stock a target price of $40. On February 18, 2025, Barclays Downgraded its rating to Equal Weight which previously was Overweight and also lowered its target price recommendation from $111 to $45.
Goldman Downgraded its Buy to Neutral on January 29, 2025, whereas the target price for the stock was revised from $99 to $51.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 11 ’25 when Hussain Abbas sold 312 shares for $28.00 per share. The transaction valued at 8,736 led to the insider holds 580 shares of the business.
Hussain Abbas bought 312 shares of MRNA for $8,736 on Jun 11 ’25. On Mar 03 ’25, another insider, Bancel Stephane, who serves as the Chief Executive Officer of the company, bought 160,314 shares for $31.22 each. As a result, the insider paid 5,004,318 and bolstered with 9,210,686 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 9765908480 and an Enterprise Value of 5375901696. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.17 while its Price-to-Book (P/B) ratio in mrq is 1.04. Its current Enterprise Value per Revenue stands at 1.747 whereas that against EBITDA is -1.754.
Stock Price History:
The Beta on a monthly basis for MRNA is 1.93, which has changed by -0.67650473 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, MRNA has reached a high of $81.61, while it has fallen to a 52-week low of $23.15. The 50-Day Moving Average of the stock is -13.58%, while the 200-Day Moving Average is calculated to be -22.94%.
Shares Statistics:
The stock has traded on average 9.53M shares per day over the past 3-months and 9330010 shares per day over the last 10 days, according to various share statistics. A total of 389.00M shares are outstanding, with a floating share count of 343.56M. Insiders hold about 11.70% of the company’s shares, while institutions hold 73.78% stake in the company. Shares short for MRNA as of 1755216000 were 62826303 with a Short Ratio of 6.59, compared to 1752537600 on 66236681. Therefore, it implies a Short% of Shares Outstanding of 62826303 and a Short% of Float of 22.37.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 12.0 analysts currently analyzing and rating the stock of Moderna Inc (MRNA).The consensus estimate for the next quarter is -$2.91, with high estimates of -$2.28 and low estimates of -$3.95.
Analysts are recommending an EPS of between -$8.86 and -$10.71 for the fiscal current year, implying an average EPS of -$9.75. EPS for the following year is -$7.52, with 17.0 analysts recommending between -$0.16 and -$10.13.
Revenue Estimates
14 analysts predict $932.29M in revenue for the current quarter. It ranges from a high estimate of $1.43B to a low estimate of $610.94M. As of the current estimate, Moderna Inc’s year-ago sales were $1.86BFor the next quarter, 14 analysts are estimating revenue of $734.77M. There is a high estimate of $895M for the next quarter, whereas the lowest estimate is $511.9M.
A total of 22 analysts have provided revenue estimates for MRNA’s current fiscal year. The highest revenue estimate was $2.28B, while the lowest revenue estimate was $1.54B, resulting in an average revenue estimate of $1.93B. In the same quarter a year ago, actual revenue was $3.24BBased on 22 analysts’ estimates, the company’s revenue will be $2.25B in the next fiscal year. The high estimate is $5.67B and the low estimate is $1.34B.
